Skip to content

Adela

3 viewers · 30d

Total raised

$5.0M

+$5.0M this year

1 filing since 2026 · latest Debt filed

Cumulative raised
LAST ROUND
Debt · $5.0M
ROUNDS
1
INVESTORS
1
FOUNDED
N/A
HQ
Foster City, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
3

AI overview

Updated

Adela develops blood-based molecular tests for detecting and monitoring cancer. Its liquid-biopsy approach analyzes cell-free DNA using genome-wide methylation enrichment combined with computational analysis, so no tumor tissue sample is required. The company's first clinically validated application monitors patient response to immunotherapy in advanced solid tumors, with results published in NPJ Precision Oncology. The underlying methylation-enrichment technology was developed by co-founder and Chief Scientific Officer Dr. Daniel De Carvalho at University Health Network's Princess Margaret Cancer Centre; Adela operates from Foster City, California and Toronto, Canada.

What sets it apart

Tissue-free, genome-wide methylation enrichment rather than targeted sequencing of a fixed mutation panel, so a single blood draw can be applied across the cancer continuum — early detection, diagnosis, and treatment monitoring — without needing a matched tumor biopsy.

Funding history

1 round
Debt+1Apr 10, 2026
Form D
+$5.0M$5.0M total

Latest SEC filings

via EDGAR · CIK 0001852167
Form D · Apr 10, 2026View on EDGAR

Products

1 tracked

Adela methylation-based blood test

Liquid biopsy diagnostic test

A liquid-biopsy test that reads genome-wide methylation patterns in cell-free DNA from a blood sample to identify cancer signals, used first for monitoring immunotherapy response in advanced solid tumors.

  • Genome-wide cell-free DNA methylation enrichment
  • Tissue-free: requires only a blood sample, no matched tumor biopsy
  • Computational analysis of epigenetic cancer signals
  • Clinically validated for immunotherapy response monitoring in advanced solid tumors, published in NPJ Precision Oncology

Links

WebsiteLinkedInSEC EDGAR filings